Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NACRE 2 phase III trial in older patients with locally advanced rectal cancer
2025-521619-37-00Phase 3Authorised
- Sponsor
- Unicancer
- Start
- Feb 2026
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of oxaliplatin, folinic acid and fluorouracil in rectal adenocarcinoma (2 arms), sponsored by Unicancer. Primary endpoints: 24-month TME-free survival and 24-month organ preservation rate. Planned start Feb 2026; status: authorised.
02
Drugs
oxaliplatinfolinic acidfluorouracil
03
Conditions
rectal adenocarcinoma
Beyond the preview
Go deeper on 2025-521619-37-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-521619-37-00.